AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Artelo Biosciences Soars 12.26% on Positive Drug Data
Generated by AI AgentAinvest Pre-Market Radar
Wednesday, Jul 9, 2025 6:02 am ET1min read
Artelo Biosciences' stock surged 12.26% in pre-market trading on July 9, 2025, driven by positive preclinical data for its drug candidate ART12.11.
Artelo Biosciences reported that ART12.11 demonstrated significant antidepressant-like effects and cognitive benefits in animal studies. The 28-day treatment regimen with ART12.11 reversed behavioral impairments in male rats exposed to chronic stress, showing efficacy comparable to sertraline, a commonly prescribed antidepressant.
The company's CEO, Gregory D. Gorgas, expressed particular encouragement over the strong antidepressant effects observed in the preclinical data. This positive data has sparked investor interest, leading to a notable increase in the stock price.
Artelo Biosciences also announced positive Phase 1 data for its non-opioid analgesic candidate, further bolstering investor confidence in the company's pipeline. The preclinical data for ART12.11 suggests its potential to treat depression and cognitive deficits associated with chronic stress, aligning with the company's goal of developing innovative therapies for mental health conditions.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
ProFrac Holding shares fell 6.49% on Dec. 17 2025 as sector risks and energy services sentiment shifts weigh
Dec.17 2025
Invivyd (IVVD) Surged 7.21% as SPEAR Study Group Recommends VYD2311 Long COVID Antibody Study Design
Dec.17 2025
ECARX Holdings surges 5.63% on renewed investor confidence in strategic direction
Dec.17 2025
Olaplex Holdings (NASDAQ:OLPX) shares surged 10.00% following Bank of America report on beauty sector growth forecast.
Dec.17 2025
Strive Inc. (NASDAQ:ASST) surged 9.02% driven by analyst upgrades and Bitcoin expansion plans ahead of earnings.
Dec.17 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet